Correlation Between NT pro-BNP, Troponin I and Inhospital Mortality in Miokard Akut Patients Who Have Already Undergone Percutaneous Coronary Intervention: a Report from ONE ACS Registry Subarea dr. Saiful Anwar Malang Hospital

Diah Ivana Sari, Setyasih Anjarwani, Ardian Rizal, Mohammad Saifur Rohman, Indra Prasetya


Introduction. Many research have looked into the potential of various biomarkers as predictors of intrahospital mortality in patients with STEMI. Patients with a history of heart failure, patients with STEMI with cardiogenic shock, and patients with heart failure all had a similar association between pro-BNP NT and intra-hospital mortality. In STEMI patients, troponin is another biomarker that can be utilized to predict intrahospital mortality with NT pro BNP.

Objective. This study looked into the correlation between NT pro BNP and troponin I and intrahospital mortality in STEMI patients who had had PCI at RSUD dr. Saiful Anwar Malang.

Material and Methods. A retrospective cohort research with an observational analysis design, targeted 391 STEMI patients who underwent PCI at RSUD dr. Saiful Anwar Malang between January 2018 and August 2022.

Result. With AUC NT pro BNP 0.840 (95% confidence interval [CI]: 0.789 – 0.892) and troponin I AUC 0.818 (95% CI: 0.753 – 0.882), the ROC curve demonstrated a high degree of discriminating. The NT pro BNP 4390 cutoff value was also derived from the ROC analysis with a sensitivity of 0.882 and a specificity of 0.882. The threshold for troponin I was 7.9, with a sensitivity of 0.725 and a specificity of 0.80. From the examination of the connection, it was determined that there was a high link between NT pro BNP and intrahospital mortality in AMI EST patients who had had PCI, with a R value of 0.70; OR 10,484 (95% confidence interval [CI]: 7,731–19,366). With a R value of 0.4, there was a moderate connection between troponin I and intrahospital mortality in STEMI patients who had had PCI; the odds ratio was 6,167 (95% confidence interval: 2,286–16,637).

Conclusion. There were a strong and moderate correlation between NT pro BNP and troponin I, respectively, with inhospital mortality in STEMI patient. 


NT pro-BNP, Troponin I, Inhospital Mortality, STEMI, PCI

Full Text:



Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's heart disease: a textbook of cardiovascular medicine. Elsevier Health Sciences; 2014

Kolansky DM. Acute coronary syndromes: morbidity, mortality and pharmacoeconomic burden. Am J Manag Care 2009;15:S36–41.

Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Departemen Kesehatan Republik Indonesia; 2018.

Theo Vos, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet, Volume 396, Issue 10258, 2020, Pages 1204-1222, ISSN 0140-6736,

Benjamin MS, et al. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry®–GWTG™. Clinical Chemistry 59:8 (2013): 1205-1214

Peng CH, et al. N-terminal pro-brain natriuretic peptide improves the C-ACS risk score prediction of clinical outcomes in patients with STelevation myocardial infarction. He et al. BMC Cardiovascular Disorders (2016) 16:255

Yash PS, et al. Role of N-terminal pro-B-type natriuretic peptide in the prediction of outcomes in ST-elevation myocardial infarction complicated by cardiogenic shock. Indian Heart Journal 72 (2020) 302e30

British Heart Foundation. Coronary heart disease statistics 2012. http://www. 2012.

Diana EC, et al. Predictors of in-Hospital Mortality of ST-Segment Elevation Myocardial Infarction Patients Undergoing Interventional Treatment. An Analysis of Data from the RO-STEMI Registry. MAEDICA – a Journal of Clinical Medicine 2015; 10(4): 295-303

Stolt Steiger V, Goy JJ, Stauffer JC – Significant decrease in in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007. Results from the AMIS registry. Swiss Med Wkly 2009;139:453-457.

Granger CB, Goldberg RJ, Dabbous O – Predictors of Hospital Mortality in The Global Registry of Acute Coronary Events. Arch Intern Med 2003;163:2345- 2353

Gale CP, Manda SO, Batin PD – Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database. Heart 2008;94:1407-1412

Brett LW, et al. Relationship Between Troponin on Presentation and In-Hospital Mortality in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Am Heart Assoc. 2019;8:e013551. DOI: 10.1161/ JAHA.119.013551

Khullar N, Buckley AJ, O’Connor C, et al. Peak troponin T in STEMI: a predictor of all-cause mortality and left ventricular function. Open Heart 2022;9:e001863. doi: 10.1136/openhrt-2021-001863

Zhao L, et al. Prognostic Implications of the Admission Cardiac Troponin I Levels and Door-to-Balloon Time on Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Therapeutics and Clinical Risk Management 2022:18 31–45

Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia. Pedoman Tatalaksana Sindroma Koroner Akut. Edisi Keempat. Jakarta : 2018

Dharma S, Andriantoro H, Dakota I, et al. Organisation of reperfusion therapy for STEMI in a developing country. Open Heart 2015;2:e000240

Tobing D. Buku Ajar Kardiovaskuler Jilid 2 Bab 43: Tatalaksana Infark Miokard Elevasi Segmen ST. Departemen Kardiologi dan Kedokteran Vaskular FKUI. Jakarta: 2017

Morrow AD. Myocardial Infarction: A companion of Braunwald’s Heart Disease. Elsevier Health Sciences; 2017

Ibanez B, James S, Agewall S. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) . European Heart Journal (2017) 00, 1–66

Widimsky P, Bilkova D, Penicka M. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years’ follow-up of the PRAGUE-2 trial. European Heart Journal (2007) 28, 679–684

Zheng W, Yu CM, Liu J, et al. Patients with ST-segment elevation of myocardial infarction miss out on early reperfusion: when to undergo delayed revascularization. Journal of Geriatric Cardiology (2017) 14: 524531

Tsai IT, Wang CP, Lu YC et al. The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovascular Disorders (2017) 17:1

Appleton DL, Abbate A. Benefits of coronary revascularization in stable patients in the short and long term after acute myocardial infarction. Interv. Cardiol. (2010) 2(1), 67–76

Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, Gibson CM, Pollack CV Jr, Ornato JP, Zalenski RJ, Penney J, Tiefenbrunn AJ, Greenland P; NRMI Investigators. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA. 2011 Nov 16;306(19):2120-7

Dharma S, Juzar DA, Firdaus I, Soerianata S, Wardeh AJ, Jukema JW. Acute myocardial infarction system of care in the third world. Neth Heart J. 2012 Jun;20(6):254-9.

Gokce A, et al. Early Prognostic Values of Cardiac Biomarkers in STEMI patients that underwent Percutaneous Coronary Intervention. Anatolian Journal of Emergency Medicine 2018;1(2); 13-17

Gian LS, Chiara P. Prognostic biomarkers in acute coronary syndrome. Ann Transl Med 2016;4(13):258

Egger KM., Lindah B. Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins. Curr Cardiol Rep (2017) 19: 29

Aleksova, A., Paldino, A., Beltrami, A., Padoan, L., Iacoviello, M., Sinagra, G., Emdin, M. & Maisel, A. 2019. Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone. Journal of Clinical Medicine, 8, 270.

Omland T. New features of troponin testing in different clinical settings. d Journal of Internal Medicine 268; 207–217

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct. 33(20):2551-67.

Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006 Mar. 151(3):654-60

Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21. 286(19):2405-12.

James SK, Lindahl B, Armstrong P, et al. A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol. 2004 Feb. 93(2-3):113-20.

Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21. 286(19):2405-12.

Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J. 2008 Feb. 155(2):208-14.

Panteghini M, Pagani F, Yeo KT, et al; Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. 2004 Feb. 50 (2):327-32.

Apple FS, Murakami MM, Christenson RH, et al. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta. 2004 Jul. 345(1-2):123-7.

Ryan RJ, Lindsell CJ, Hollander JE, et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med. 2009 Mar. 53(3):321-8.

ohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997 Aug 14. 337(7):447-52

Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996 Mar 2. 347(9001):561-8.

Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002 Sep 18. 40(6):1044-50.

Omland T. New features of troponin testing in different clinical settings. d Journal of Internal Medicine 268; 207–217

Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jun 11. 61(23):e179-347

Benmachiche, M., Marques-Vidal, P., Waeber, G. & Méan, M. 2018. In-hospital mortality is associated with high NT-proBNP level. PLOS ONE, 13, e0207118.

Khanam, S. S., Son, J.-W., Lee, J.-W., Youn, Y. J., Yoon, J., Lee, S.-H., Kim, J.Y., Ahn, S. G., Ahn, M.-S. & Yoo, B.-S. 2017. Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure. BMC Cardiovascular Disorders, 17, 215.

York, M. K., Gupta, D. K., Reynolds, C. F., Farber-Eger, E., Wells, Q. S., Bachmann, K. N., Xu, M., Harrell, F. E. & Wang, T. J. 2018. B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. Journal of the American College of Cardiology, 71, 2079-2088.



  • There are currently no refbacks.

Copyright (c) 2023 Indra Prasetya

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.